- ►nih.gov - Free from Publisher R van Ginderdeuren, E van Limbergen, W … - British Journal of Ophthalmology, 2005 - bjo.bmj.com Results: The median follow up time was 6.7 years (0.5–18.8 years). Actuarial
melanoma free patient survival rate was 85% (SE 4.8%) after 18 years. Actuarial
rate of ocular conservation and complete tumour regression was 90% (SE ... Related articles - BL Direct - All 11 versions
H Klaus, P Karl Lommatzsch, U Fuchs - Graefe's Archive for Clinical and Experimental …, 1991 - Springer Abstract. Choroidal malignant melanomas were exam- ined after unsuccessful
brachytherapy with l°6Ru/l°6Rh ophthalmic plaques. The histologic findings
were com- pared with those obtained in non-irradiated melanomas similar in ... Cited by 10 - Related articles - All 4 versions
R Parys-Van Ginderdeuren, JJ Van den Oord, … - Bulletin de la SociÊtÊ belge d'ophtalmologie, 1997 - ncbi.nlm.nih.gov Three patients with a choroidal melanoma, treated with HDR (High Dose Rate)
Strontium-90 brachytherapy, underwent an enucleation. Radiation effect was only
visible at the irradiation zone with a brisk transition to normal tissue. ... Cited by 3 - Related articles - BL Direct - All 3 versions
L Missotten, W Dirven, A Van der Schueren, … - Graefe's Archive for Clinical and Experimental …, 1998 - Springer Page 1. Graefe s Arch Clin Exp Ophthalmol (1998) 236:164±173 Springer-Verlag
1998 CLINICALINVESTIGATION Luc Missotten Werner Dirven ... Cited by 3 - Related articles
R Pötter, E Van Limbergen - The GEC ESTRO handbook of brachytherapy. pp591– … - estroweb.org Uveal melanoma account for about 75% of all primary malignant intraocular
tumours (20% retinoblastoma). Eye melanoma is a rare malignancy with a mean
incidence of less than one new case per 100.000 inhabitants and year (from ... Cited by 2 - Related articles - View as HTML - All 5 versions
S Seregard, G Lundell, I Lax, E Trampe, E … - Acta Ophthalmologica Scandinavica, 1997 - interscience.wiley.com ABSTRACT. Enucleation following ruthenium plaque radiotherapy for posterior
uveal melanoma indicates failure of treatment. This study focused on the
histopathological findings and remaining tumour cell growth fraction in 42 ... Cited by 12 - Related articles - BL Direct - All 2 versions
P Summanen, I Immonen, T Kivelä, P Tommila … - Ophthalmic surgery and lasers - ncbi.nlm.nih.gov BACKGROUND AND OBJECTIVE: To analyze the overall visual outcome in 100
consecutive eyes with malignant uveal melanoma irradiated with ruthenium-106
plaques between 1981 and 1991. PATIENTS AND METHODS: The follow-up ranged ... Cited by 12 - Related articles - BL Direct - All 4 versions
R Guthoff, D von Domarus, U Steinhorst, D … - Klinische Monatsblätter für Augenheilkunde, 1986 - cat.inist.fr 10 Jahre Erfahrung mit der Ruthenium-106/Rhodium-106-Behandlung des malignen
Melanoms der Aderhaut-Bericht über 264 bestrahlte Tumoren. ... Cited by 12 - Related articles
PA Sieving - Archives of Ophthalmology, 2001 - Am Med Assoc CHOROIDAL MELANOMA is the most common primary ocular malignancy, with some 1500
new cases reported yearly in the United States. These tumors are both sight- and
life-threatening, with approximately a 10% to 30% five-year mortality rate ... Cited by 13 - Related articles - BL Direct - All 3 versions
AW Jensen, IA Petersen, RW Kline, SL … - International journal of radiation oncology, biology, …, 2005 - Elsevier Results: With a median follow-up of 6.2 years, the 5-year overall survival was
83%. The 5-year disease-specific survival was 91%. Initial local control at 5
years was 92%, with 100% ultimate local control after secondary therapy ... Cited by 9 - Related articles - All 20 versions
